emerging glp-1 gip weight loss treatments 2025 Nutritional priorities to support therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society List of approved and pending

[DOI] [PMC free article] [PubMed] [Google Scholar] 104.Pfeffer M.A., Claggett B., Diaz R., Dickstein K., Gerstein H.C., Kber L.V., Lawson F.C., Ping L., Wei X., Lewis E.F., et al

[10] In the 12-week study on middle-aged women cited above, the researchers found that HMB has an incredible ability to reduce intramuscular adipose tissue (IMAT), a type of fat infiltration within muscle tissue that can compromise metabolic health

According to NICE Technology Appraisal (TA875), Wegovy is recommended for adults with a BMI of at least 35 kg/m (or lower thresholds for certain ethnic groups) who have at least one weight-related comorbidity

North America leads with 50.14% share in 2024, supported by high diabetes prevalence and advanced treatment adoption

The convergence of oral bioavailability and multi-receptor agonism is redefining the landscape of obesity and diabetes therapeutics

In summary, GLP-1 receptor agonists exert anti-fibrotic effects in MASLD through the inhibition of hepatic stellate cell activation, the modulation of profibrotic signaling pathways, and the promotion of hepatocyte regeneration